PT - JOURNAL ARTICLE AU - S.K. Mukherji TI - Bevacizumab (Avastin) AID - 10.3174/ajnr.A1987 DP - 2010 Feb 01 TA - American Journal of Neuroradiology PG - 235--236 VI - 31 IP - 2 4099 - http://www.ajnr.org/content/31/2/235.short 4100 - http://www.ajnr.org/content/31/2/235.full SO - Am. J. Neuroradiol.2010 Feb 01; 31 AB - SUMMARY: Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent. FDAU.S. Food and Drug AdministrationVEGFvascular endothelial growth factor